Epiglottitis medical therapy: Difference between revisions
Line 57: | Line 57: | ||
<font color="#FFF"> | <font color="#FFF"> | ||
'''Bacteria''' | '''Bacteria''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 81: | Line 75: | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Staphylococcus aureus''''' | ▸ '''''Staphylococcus aureus''''' | ||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table18" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''''Haemophilus influenzae type B''''' | |||
</font> | </font> | ||
</div> | </div> | ||
Line 88: | Line 88: | ||
▸ '''''Klebsiella pneumoniae''''' | ▸ '''''Klebsiella pneumoniae''''' | ||
</font> | </font> | ||
</div><div class="mw-customtoggle-table22" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | </div> | ||
<div class="mw-customtoggle-table22" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | |||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Moraxella catarrhalis''''' | ▸ '''''Moraxella catarrhalis''''' | ||
Line 132: | Line 134: | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus pneumoniae''}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus pneumoniae''}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen (sussceptible to penicillin)''' | ||
|- | |- | ||
| style=" | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 2 million units IV q4h'''''<BR> OR <BR> ▸ ''''' '''''[[Ceftriaxone]] 2 g IV q24h'''''<BR> OR <BR> '''''[[Clindamycin]] 600 mg IV q6h''''' | ||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen (penicillin resistant strains)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]] 750 mgIV q24h'''''<BR> OR <BR> ▸ '''''[[Vancomycin]] 1 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Ceftaroline]] 600 mg IV q12h''''' | |||
|- | |||
|} | |} | ||
|} | |} | ||
Line 145: | Line 147: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus pyogenes''}} | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus viridans''}} | |||
|} | |||
|} | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Meticillin susceptible Staphylococcus aureus''}} | |||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen''' | ||
Line 159: | Line 168: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL> | ||
|- | |- | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Meticilling resistant Staphylococcus aureus''}} | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus''}} | |||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8-12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4-6 mg/kg IV q24h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h''''' | ||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen (Vancomycin intermmediate sussceptibility)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 600 mg/kg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4-6 mg/kg IV q24h'''''<BR> OR <BR>▸ '''''[[Ceftraoline]] 600 mg IV q8h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen (Vancomycin resistance)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Teicoplanin]] 6 mg/kg IV q12h (total of three doses), 6 mg/kg IV q24h'''''<BR> OR <BR> ▸ '''''[[Telavancin]] 10 mg/kg q24h (1 hour infusion)'''''<BR> OR <BR>▸ '''''[[Linezolid]] 600 mg/kg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4-6 mg/kg IV q24h''''' | ||
|- | |- | ||
|} | |} |
Revision as of 16:15, 19 May 2014
Epiglottitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Epiglottitis medical therapy On the Web |
American Roentgen Ray Society Images of Epiglottitis medical therapy |
Risk calculators and risk factors for Epiglottitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Medical Therapy
Patients should receive empiric antibiotic treatment after sample for throat culture has been taken. The recomended treatment is a combination of a third generation cephaplosporin such as ceftriaxone or cefotaxime with an antistaphylococcal agent, active against.Template:Cita publicación
Empiric Therapy Adapted from Lancet. 2012;380(9854):1693-702.[1] and Clin Infect Dis. 2004;39(9):1267-84.[2]
|